Loading clinical trials...
Loading clinical trials...
A Phase IIIb, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of IVT 0.5mg Ranibizumab Monthly Compared to a Treat & Extend Protocol in Patients With Wet Age-related Macular Degeneration (T-REX)
Conditions
Interventions
0.5 mg ranibizumab
Locations
4
United States
Palmetto Retina Center
West Columbia, South Carolina, United States
Retina Consultants of Houston/The Medical Center
Houston, Texas, United States
Retina Consultants of Houston/Katy office
Katy, Texas, United States
Retina Consultants of Houston
The Woodlands, Texas, United States
Start Date
December 1, 2012
Primary Completion Date
February 1, 2017
Completion Date
February 1, 2017
Last Updated
June 4, 2019
NCT05913063
NCT07446582
NCT06779773
NCT06990269
NCT06970665
NCT07160179
Lead Sponsor
Charles C Wykoff, PhD, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions